MedTrace Logo

Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study

NCT03437382 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-03-18

No results posted yet for this study

Summary

In this multi-center, dose-finding study, patients with early stage hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer (BCLC) staging system will be included to receive percutaneous radiofrequency ablation in combination with RFA with adjuvant segmental radioembolization.

Conditions

  • HCC
  • Early Stage HCC

Interventions

DEVICE

Quirem Medical Holmium-166 radioembolization microspheres

radioembolisation as adjuvant treatment to RFA

Sponsors & Collaborators

  • ZonMw: The Netherlands Organisation for Health Research and Development

    collaborator OTHER

  • Health Holland

    collaborator OTHER

  • Quirem Medical B.V.

    collaborator INDUSTRY

  • Medtronic

    collaborator INDUSTRY

  • Maag Lever Darm Stichting

    collaborator OTHER

  • Leiden University Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2021-03-17
Completion
2021-03-17

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03437382 on ClinicalTrials.gov